Diffuse large B-cell lymphoma refractory

14 trials 6 recruiting MedDRA PT
14 Registered trials
6 Recruiting
12 Unique sponsors
31 Unique IMPs
14 Commercial trials
Drug classes (ATC)
— ATC code not specified 7
A Gastroenterology (ATC A) 1
H Endocrinology (ATC H) 2
J Anti-infectives (ATC J) 1
L Oncology (ATC L) 7
N Neurology/Psychiatry (ATC N) 2
R Respiratory (ATC R) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 9 substances
Antimetabolite 2 substances
Corticosteroid 2 substances
CAR-T cell therapy 2 substances
Monoclonal antibody 2 substances
Monoclonal antibody (tumor, humanized) 2 substances
IMiD 2 substances
BTK inhibitor 2 substances
Alkylating agent 1 substance
Antiviral 1 substance
Analgesic / antipyretic 1 substance
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (chimeric) 1 substance
Antibody-drug conjugate (ADC) 1 substance
Anthracycline 1 substance
BCL-2 inhibitor 1 substance
Phase III: 3 Phase II: 4 Phase I/II: 2 Phase I: 5

Filter these 14 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 14 trials

Phase III

3 trials
  • F. Hoffmann-La Roche AG Commercial
    GLOFITAMAB; OBINUTUZUMAB; RITUXIMAB; TOCILIZUMAB
    2023-506899-27-00 6 countries 2021 n=85
    Ended
  • F. Hoffmann-La Roche AG Commercial
    POLATUZUMAB VEDOTIN; RITUXIMAB
    2024-512537-33-00 5 countries 2019 n=49 Orphan
    Ended
  • Seagen Inc. Commercial
    LENALIDOMIDE
    2023-503384-41-00 7 countries 2020 n=84 Orphan
    Ended

Phase II

4 trials
  • Allogene Therapeutics Inc. Commercial
    ALLO-501A; ALLO-647; CYCLOPHOSPHAMIDE; FAMOTIDINE; FLUDARABINE PHOSPHATE; FLUDARABINE PHOSPHATE PH. EUR.; HYDROCORTISONE; LETERMOVIR; LORATADINE; PARACETAMOL; PROMETHAZINE HYDROCHLORIDE; TOCILIZUMAB
    2023-503830-27-00 3 countries 2023 n=35
    Ended
  • AstraZeneca AB Commercial
    HUMAN IGG4 KAPPA MONOCLONAL ANTIBODY AGAINST CD3 AND CD19; SUROVATAMIG
    2023-505789-27-00 6 countries 2025 n=82
    Recruiting
  • F. Hoffmann-La Roche AG Commercial
    IMP not specified
    2024-516791-15-00 3 countries 2025 n=26
    Recruiting
  • Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial
    AXICABTAGENE CILOLEUCEL; GLOFITAMAB; LISOCABTAGENE MARALEUCEL; OBINUTUZUMAB
    2025-523806-34-00 1 country n=20 Orphan
    Pending

Phase I/II

2 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    CYCLOPHOSPHAMIDE; DOXORUBICIN HYDROCHLORIDE; EPCORITAMAB; GOLCADOMIDE; IBRUTINIB; LENALIDOMIDE; POLATUZUMAB VEDOTIN; PREDNISOLONE; RITUXIMAB; VENETOCLAX
    2023-505347-38-00 7 countries 2022 n=59 Orphan
    Recruiting
  • BeOne Medicines AG Commercial
    BGB-16673; GLOFITAMAB; MOSUNETUZUMAB; N-[4-({[(1R,4R)-4-HYDROXY-4-METHYLCYCLOHEXYL]METHYL}AMINO)-3- NITROBENZENE-1-SULFONYL]-4-(2-{(2S)-2-[2-(PROPAN-2-YL)PHENYL]PYRROLIDIN1-YL}-7-AZASPIRO[3.5]NONAN-7-YL)-2-[(1H-PYRROLO[2,3-B]PYRIDIN-5- YL)OXY]BENZAMIDE; OBINUTUZUMAB; ZANUBRUTINIB
    2024-516234-35-00 3 countries 2025 n=99 Orphan
    Recruiting

Phase I

5 trials
  • Biomea Fusion Inc. Commercial
    IMP not specified
    2024-515744-23-00 2 countries 2023 n=30
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2023-509969-20-00 2 countries 2017 n=127
    Ended
  • Emercell SAS Commercial
    IMP not specified
    2024-511843-24-00 1 country n=10
    Pending
  • Exscientia AI Limited Commercial
    IMP not specified
    2024-516869-36-00 5 countries 2025 n=101
    Recruiting
  • Famicordtx S.A. Commercial
    IMP not specified
    2025-520653-37-00 1 country 2025 n=6
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
F. Hoffmann-La Roche AG Commercial 3 Phase II, Phase III 1
Biomea Fusion Inc. Commercial 1 Phase I 0
Celgene Corp. Commercial 1 Phase I 0
Emercell SAS Commercial 1 Phase I 0
Exscientia AI Limited Commercial 1 Phase I 1
Famicordtx S.A. Commercial 1 Phase I 1
Allogene Therapeutics Inc. Commercial 1 Phase II 0
AstraZeneca AB Commercial 1 Phase II 1
Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH Commercial 1 Phase II 0
Seagen Inc. Commercial 1 Phase III 0
AbbVie Deutschland GmbH & Co. KG Commercial 1 Phase I/II 1
BeOne Medicines AG Commercial 1 Phase I/II 1
New trials by year
2019
1
2020
1
2021
1
2022
1
2023
2
2025
5
← All indication landscapes